SG11201900796UA - Prophylactic or therapeutic agent for vascular disorder - Google Patents

Prophylactic or therapeutic agent for vascular disorder

Info

Publication number
SG11201900796UA
SG11201900796UA SG11201900796UA SG11201900796UA SG11201900796UA SG 11201900796U A SG11201900796U A SG 11201900796UA SG 11201900796U A SG11201900796U A SG 11201900796UA SG 11201900796U A SG11201900796U A SG 11201900796UA SG 11201900796U A SG11201900796U A SG 11201900796UA
Authority
SG
Singapore
Prior art keywords
prophylactic
therapeutic agent
vascular disorder
cell
vascular
Prior art date
Application number
SG11201900796UA
Other languages
English (en)
Inventor
Yoshikatsu Saiki
Mari Dezawa
Katsuhiro Hosoyama
Original Assignee
Univ Tohoku
Life Science Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tohoku, Life Science Institute Inc filed Critical Univ Tohoku
Publication of SG11201900796UA publication Critical patent/SG11201900796UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201900796UA 2016-07-29 2017-07-28 Prophylactic or therapeutic agent for vascular disorder SG11201900796UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016150542 2016-07-29
PCT/JP2017/027383 WO2018021515A1 (ja) 2016-07-29 2017-07-28 血管障害の予防又は治療剤

Publications (1)

Publication Number Publication Date
SG11201900796UA true SG11201900796UA (en) 2019-02-27

Family

ID=61016611

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900796UA SG11201900796UA (en) 2016-07-29 2017-07-28 Prophylactic or therapeutic agent for vascular disorder

Country Status (10)

Country Link
US (1) US11419899B2 (ko)
EP (1) EP3492091B1 (ko)
JP (1) JP7029729B2 (ko)
KR (1) KR102360990B1 (ko)
CN (1) CN109843308A (ko)
AU (1) AU2017303905B2 (ko)
CA (1) CA3032358A1 (ko)
ES (1) ES2882702T3 (ko)
SG (1) SG11201900796UA (ko)
WO (1) WO2018021515A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019388016A1 (en) * 2018-11-30 2021-07-08 Kyoto Prefectural Public University Corporation Therapeutic agent of peripheral blood flow disorder
WO2021029346A1 (ja) * 2019-08-09 2021-02-18 国立大学法人東北大学 脳血管性認知症の治療または予防剤
JPWO2022138955A1 (ko) * 2020-12-25 2022-06-30

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD297962A5 (de) 1990-07-05 1992-01-30 �������@������������@��k�� Verfahren zur herstellung von 5-carbamoyl-5h-dibenz/b,f/azepin
DE60020681T9 (de) * 1999-02-23 2006-08-31 Angiotech International Ag Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
CA2777783A1 (en) * 2009-10-13 2011-04-21 Allocure Inc. Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
WO2014027474A1 (ja) 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ 心筋梗塞の修復再生を誘導する多能性幹細胞
JP5747255B2 (ja) * 2013-07-09 2015-07-08 株式会社サンセイアールアンドディ 遊技機
JP6519038B2 (ja) 2014-02-26 2019-05-29 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
JP6452107B2 (ja) 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
EP3808367A3 (en) * 2014-09-15 2021-07-21 The Board of Trustees of the Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways

Also Published As

Publication number Publication date
KR102360990B1 (ko) 2022-02-08
AU2017303905A1 (en) 2019-02-21
EP3492091A1 (en) 2019-06-05
US11419899B2 (en) 2022-08-23
JP7029729B2 (ja) 2022-03-04
US20190175662A1 (en) 2019-06-13
WO2018021515A1 (ja) 2018-02-01
AU2017303905B2 (en) 2022-11-10
CA3032358A1 (en) 2018-02-01
CN109843308A (zh) 2019-06-04
EP3492091B1 (en) 2021-07-14
EP3492091A4 (en) 2020-02-26
ES2882702T3 (es) 2021-12-02
KR20190035726A (ko) 2019-04-03
JPWO2018021515A1 (ja) 2019-05-23

Similar Documents

Publication Publication Date Title
MX2021000614A (es) Células diferenciadas de células pluripotentes inmunodiseñadas.
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MY188696A (en) Cysteine protease
MX2010001401A (es) Productos medicos mejorados, revestidos con preparaciones farmaceuticas, la produccion de los mismos y el uso de los mismos.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
SG11201900796UA (en) Prophylactic or therapeutic agent for vascular disorder
MX336013B (es) Dispositivos, sistemas y metodos de administracion terapeuticos.
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
MX2020000713A (es) Metodos de aferesis y sus usos.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
MX2018015172A (es) Metodos para tratar cancer pancreatico.
WO2018220489A3 (en) METHODS OF OBTAINING CELLS FROM HUMAN OMBILICAL POST-PARTUM CORDON ARTERIAL TISSUE
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2019014867A (es) Metodo para tratar un efecto secundario de la inmunoterapia.